{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:31:08Z","timestamp":1779103868899,"version":"3.51.4"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00513","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T06:06:55Z","timestamp":1542002815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers"],"prefix":"10.3389","volume":"8","author":[{"given":"Claudia","family":"Rossig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sareetha","family":"Kailayangiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Jamitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Altvater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma-subunit or zeta-subunit of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","author":"Keu","year":"2017","journal-title":"Sci Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1158\/0008-5472.CAN-08-0999","article-title":"Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells","volume":"69","author":"Roesli","year":"2009","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","article-title":"Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma","volume":"5","author":"Cheung","year":"1987","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01756188","article-title":"A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14","volume":"35","author":"Handgretinger","year":"1992","journal-title":"Cancer Immunol Immunother."},{"key":"B26","first-page":"4474","article-title":"Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.4049\/jimmunol.1200934","article-title":"Intratumoral hu14","volume":"189","author":"Yang","year":"2012","journal-title":"J Immunol."},{"key":"B28","first-page":"401","article-title":"Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells","volume":"5","author":"Mezzanzanica","year":"1998","journal-title":"Cancer Gene Ther."},{"key":"B29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens","volume":"73","author":"Zhang","year":"1997","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1073\/pnas.0709619104","article-title":"Ganglioside GM2\/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82\/cMet-mediated pathway","volume":"105","author":"Todeschini","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.4049\/jimmunol.0901409","article-title":"Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody","volume":"183","author":"Hu","year":"2009","journal-title":"J Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1469-7580.2002.00030.x","article-title":"Surface antigens of human embryonic stem cells: changes upon differentiation in culture","volume":"200","author":"Draper","year":"2002","journal-title":"J Anat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2006-08-039347","article-title":"Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs","volume":"109","author":"Martinez","year":"2007","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064454","article-title":"Generation of murine sympathoadrenergic progenitor-like cells from embryonic stem cells and postnatal adrenal glands","author":"Saxena","year":"2013","journal-title":"PLoS ONE"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e00054","DOI":"10.1042\/AN20110006","article-title":"Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells","volume":"3","author":"Yanagisawa","year":"2011","journal-title":"ASN Neuro"},{"key":"B37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ijc.2910410303","article-title":"Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma","volume":"41","author":"Hersey","year":"1988","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0482","article-title":"Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin","author":"Krug","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B39","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1073\/pnas.79.24.7629","article-title":"Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2","volume":"79","author":"Cahan","year":"1982","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.2910530614","article-title":"Shedding of GD2 ganglioside in patients with retinoblastoma","volume":"53","author":"Portoukalian","year":"1993","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/pbc.26097","article-title":"Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults","volume":"63","author":"Dobrenkov","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mpo.10151","article-title":"Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor","volume":"39","author":"Modak","year":"2002","journal-title":"Med Pediatr Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"31592","DOI":"10.18632\/oncotarget.16363","article-title":"GD2 expression in breast cancer","volume":"8","author":"Orsi","year":"2017","journal-title":"Oncotarget"},{"key":"B49","first-page":"4244","article-title":"Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis","volume":"61","author":"Yoshida","year":"2001","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/j.1471-4159.2007.04910.x","article-title":"Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains","volume":"103","author":"Ngamukote","year":"2007","journal-title":"J Neurochem."},{"key":"B51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1471-4159.1996.66010026.x","article-title":"Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development","volume":"66","author":"Yamamoto","year":"1996","journal-title":"J Neurochem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10059-009-0012-4","article-title":"Valproic acid induces transcriptional activation of human GD3 synthase (hST8Sia I) in SK-N-BE(2)-C human neuroblastoma cells","volume":"27","author":"Kwon","year":"2009","journal-title":"Mol Cells"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","article-title":"Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis","volume":"122","author":"Battula","year":"2012","journal-title":"J Clin Invest."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062559","article-title":"Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFkappaB binding to ST8SIA1 promoter","author":"Bobowski","year":"2013","journal-title":"PLoS ONE"},{"key":"B55","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10719-016-9719-6","article-title":"Epigenetic regulation of ganglioside expression in neural stem cells and neuronal cells","volume":"34","author":"Itokazu","year":"2017","journal-title":"Glycoconj J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jnc.12456","article-title":"Epigenetic activation of mouse ganglioside synthase genes: implications for neurogenesis","volume":"128","author":"Tsai","year":"2014","journal-title":"J Neurochem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1471-4159.2010.07042.x","article-title":"Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development","volume":"116","author":"Suzuki","year":"2011","journal-title":"J Neurochem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10719-012-9423-0","article-title":"Disialyl gangliosides enhance tumor phenotypes with differential modalities","volume":"29","author":"Furukawa","year":"2012","journal-title":"Glycoconj J."},{"key":"B59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/glycob\/9.2.101","article-title":"Tenascin-C inhibits beta1 integrin-dependent cell adhesion and neurite outgrowth on fibronectin by a disialoganglioside-mediated signaling mechanism","volume":"9","author":"Probstmeier","year":"1999","journal-title":"Glycobiology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/sj.onc.1210770","article-title":"Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility","volume":"27","author":"Wu","year":"2008","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.febslet.2009.12.010","article-title":"Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction","volume":"584","author":"Posse","year":"2010","journal-title":"FEBS Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/onc.2014.245","article-title":"GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer","volume":"34","author":"Sarkar","year":"2014","journal-title":"Oncogene"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-14-0927","article-title":"Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells","volume":"74","author":"Wondimu","year":"2014","journal-title":"Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B65","first-page":"440","article-title":"Expression of GD2 ganglioside by untreated primary human neuroblastomas","volume":"46","author":"Wu","year":"1986","journal-title":"Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pain.2010.01.024","article-title":"Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia","volume":"149","author":"Sorkin","year":"2010","journal-title":"Pain"},{"key":"B67","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4049\/jimmunol.144.4.1382","article-title":"Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody","volume":"144","author":"Mueller","year":"1990","journal-title":"J Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2004.08.143","article-title":"Consolidation treatment with chimeric anti-GD2-antibody ch14","volume":"22","author":"Simon","year":"2004","journal-title":"J Clin Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3389\/fimmu.2018.01355","article-title":"A Comprehensive safety trial of chimeric antibody 14","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0043-103086","article-title":"GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors","volume":"229","author":"Simon","year":"2017","journal-title":"Klin Padiatr."},{"key":"B74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/1096-911X(20010101)36:1","article-title":"Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma","volume":"36","author":"Kramer","year":"2001","journal-title":"Med Pediatr Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2001.19.22.4189","article-title":"Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma","volume":"19","author":"Kushner","year":"2001","journal-title":"J Clin Oncol."},{"key":"B76","first-page":"2857","article-title":"Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14","volume":"49","author":"Mujoo","year":"1989","journal-title":"Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CJI.0b013e31819b7c8e","article-title":"The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum","volume":"32","author":"Westwood","year":"2009","journal-title":"J Immunother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.gt.3300813","article-title":"A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA","volume":"6","author":"Hombach","year":"1999","journal-title":"Gene Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy","volume":"99","author":"Rossig","year":"2002","journal-title":"Blood"},{"key":"B82","unstructured":"CAR T Cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma221424 HeczeyA LouisCU SavoldoB DakhovaO DurettA GrilleyB 10.1016\/j.ymthe.2017.05.01228602436Mol Ther.252017"},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-CT145","volume-title":"A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-Cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma","author":"Straathof","year":"2018"},{"key":"B84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/2326-6066.CIR-18-0089","article-title":"Neurotoxicity associated with a high-affinity GD2 CAR-letter","volume":"6","author":"Majzner","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br J Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/bjc.2013.356","article-title":"Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging","volume":"109","author":"Liebsch","year":"2013","journal-title":"Br J Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025220","article-title":"A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity","author":"Alvarez-Rueda","year":"2011","journal-title":"PLoS ONE"},{"key":"B90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2013.01.032","article-title":"Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo","volume":"333","author":"Cochonneau","year":"2013","journal-title":"Cancer Lett."},{"key":"B91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/cbr.2006.21.561","article-title":"A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma","volume":"21","author":"Forero","year":"2006","journal-title":"Cancer Biother Radiopharm."},{"key":"B92","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000353","article-title":"Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma","volume":"27","author":"Tarhini","year":"2017","journal-title":"Melanoma Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-10-0043","article-title":"Anti-GD3 chimeric sFv-CD28\/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors","volume":"16","author":"Lo","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.neo.7900108","article-title":"Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors","volume":"2","author":"Yun","year":"2000","journal-title":"Neoplasia"},{"key":"B95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biochi.2017.03.001","article-title":"Aberrant ganglioside composition in glioblastoma multiforme and peritumoral tissue: a mass spectrometry characterization","volume":"137","author":"Fabris","year":"2017","journal-title":"Biochimie"},{"key":"B96","first-page":"126","article-title":"Ganglioside content and composition in human gliomas","volume":"43","author":"Gaini","year":"1988","journal-title":"Acta Neurochir Suppl."},{"key":"B97","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1073\/pnas.1604721113","article-title":"Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity","volume":"113","author":"Yeh","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B98","doi-asserted-by":"crossref","first-page":"15866","DOI":"10.1074\/jbc.273.25.15866","article-title":"The molecular basis for the absence of N-glycolylneuraminic acid in humans","volume":"273","author":"Irie","year":"1998","journal-title":"J Biol Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/0008-5472.CAN-05-2615","article-title":"Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells","volume":"66","author":"Yin","year":"2006","journal-title":"Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/0008-5472.CAN-10-4102","article-title":"Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer","volume":"71","author":"Padler-Karavani","year":"2011","journal-title":"Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"245181","DOI":"10.1155\/2011\/245181","article-title":"Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer","volume":"2011","author":"Scursoni","year":"2011","journal-title":"Clin Dev Immunol."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12578","article-title":"Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours","author":"Torbidoni","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/pbc.25631","article-title":"A Phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies","volume":"62","author":"Cacciavillano","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"26474","DOI":"10.1074\/jbc.M213223200","article-title":"Human alpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1684\/abc.2008.0224","article-title":"Biology and potential of human embryonic stem cells","volume":"66","author":"Tondeur","year":"2008","journal-title":"Ann Biol Clin."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/10","article-title":"Prospective isolation and characterization of human bone marrow-derived MSCs","volume":"129","author":"Harichandan","year":"2013","journal-title":"Adv Biochem Eng Biotechnol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"690415","DOI":"10.1155\/2013\/690415","article-title":"Isolation of small SSEA-4-positive putative stem cells from the ovarian surface epithelium of adult human ovaries by two different methods","volume":"2013","author":"Virant-Klun","year":"2013","journal-title":"Biomed Res Int."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1182\/blood-2005-11-010504","article-title":"SSEA-4 identifies mesenchymal stem cells from bone marrow","volume":"109","author":"Gang","year":"2007","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/j.1460-2075.1983.tb01746.x","article-title":"Stage-specific embryonic antigens (SSEA-3 and\u22124) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells","volume":"2","author":"Kannagi","year":"1983","journal-title":"EMBO J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.1038\/srep09604","article-title":"mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep."},{"key":"B111","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/glycob\/cwv032","article-title":"Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells","volume":"25","author":"Sivasubramaniyan","year":"2015","journal-title":"Glycobiology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13058-015-0652-6","article-title":"The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features","volume":"17","author":"Aloia","year":"2015","journal-title":"Breast Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1073\/pnas.1400283111","article-title":"Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers","volume":"111","author":"Lou","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01740","article-title":"Development of a CAR T cell therapy for the treatment of chemoresistant subpopulations in solid tumors (Abstract)","author":"Pfeifer","year":"2016","journal-title":"Hum Gene Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nm.2414","article-title":"Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport","volume":"17","author":"Ohtsubo","year":"2011","journal-title":"Nat Med."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125994","article-title":"The breast cancer-associated glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL","author":"Beatson","year":"2015","journal-title":"PLoS ONE"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1535-7163.MCT-17-0232","article-title":"A novel therapeutic strategy for pancreatic cancer: targeting cell surface glycan using rBC2LC-N Lectin-Drug Conjugate (LDC)","volume":"17","author":"Shimomura","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2015.09.003","article-title":"Targeting human cancer by a glycosaminoglycan binding malaria protein","volume":"28","author":"Salanti","year":"2015","journal-title":"Cancer Cell"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1541-7786.MCR-16-0103","article-title":"Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility","volume":"14","author":"Clausen","year":"2016","journal-title":"Mol Cancer Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/s41467-018-05793-2","article-title":"The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner","volume":"9","author":"Agerbaek","year":"2018","journal-title":"Nat Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nbt735","article-title":"Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions","volume":"20","author":"Fukui","year":"2002","journal-title":"Nat Biotechnol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ab.2008.07.023","article-title":"High-throughput screening of cell lysates for ganglioside synthesis","volume":"382","author":"Hancock","year":"2008","journal-title":"Anal Biochem."},{"key":"B125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1255\/ejms.1009","article-title":"High-throughput analysis of gangliosides in defined regions of fetal brain by fully automated chip-based nanoelectrospray ionization multi-stage mass spectrometry","volume":"15","author":"Serb","year":"2009","journal-title":"Eur J Mass Spectrom."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.5301\/JBM.2012.10361","article-title":"Surface markers in stem cells and cancer from the perspective of glycomic analysis","author":"Cho","year":"2012","journal-title":"Int J Biol Markers"},{"key":"B127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T Cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/gt.2016.38","article-title":"Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies","volume":"23","author":"Roellecke","year":"2016","journal-title":"Gene Ther."},{"key":"B132","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible Activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov."},{"key":"B136","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T23:34:00Z","timestamp":1694043240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":136,"alternative-id":["10.3389\/fonc.2018.00513"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00513","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"article-number":"513"}}